Analyst Research Report Snapshot

Title:

PHYTOPHARM - COMPETITION THINS OUT

Price:

$10.00

Provider:

Edison Investment Research

Date:

17 Sep 2007

Pages:

7

Type:

AcrobatPDF

Companies referenced:

PYM.L

Available for Immediate Download
Summary:

The discontinuation from trials of a second disease-modifying Phase III product for Alzhiemer’s disease should significantly increase the value of Phytopharm’s Cogane, one of few such products left. It endorses the UK firm’s more cautious strategy of targeting the lower-risk Parkinson’s indication, as well as orphan CNS conditions, in the first instance. However, the demise of Sanofi-Aventis’ xaliproden in Alzheimer’s may inject some uncertainty over the mechanism of action. FOR MORE INFORMATION ON ATTACHED RESEARCH PLEASE CALL 020 7190 1755 OR EMAIL RESEARCH@EDISONINVESTMENTRESEARCH.CO.UK OR VISIT WWW.EDISONINVESTMENTRESEARCH.CO.UK

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.